Next Article in Journal
Optimization and Prediction of Ibuprofen Release from 3D DLP Printlets Using Artificial Neural Networks
Next Article in Special Issue
Strategic Approaches for Colon Targeted Drug Delivery: An Overview of Recent Advancements
Previous Article in Journal
Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer
Previous Article in Special Issue
Liposomal Formulations for Nose-to-Brain Delivery: Recent Advances and Future Perspectives
Open AccessReview

Active Cellular and Subcellular Targeting of Nanoparticles for Drug Delivery

Center for Bio/Molecular Science and Engineering, Naval Research Laboratory, Code 6900, 4555 Overlook Ave. SW, Washington, DC 20375, USA
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2019, 11(10), 543; https://doi.org/10.3390/pharmaceutics11100543
Received: 8 September 2019 / Revised: 11 October 2019 / Accepted: 14 October 2019 / Published: 18 October 2019
(This article belongs to the Special Issue Advanced Formulation Approaches for Targeted Drug Delivery)
Nanoparticle (NP)-mediated drug delivery (NMDD) for active targeting of diseases is a primary goal of nanomedicine. NPs have much to offer in overcoming the limitations of traditional drug delivery approaches, including off-target drug toxicity and the need for the administration of repetitive doses. In the last decade, one of the main foci in NMDD has been the realization of NP-mediated drug formulations for active targeted delivery to diseased tissues, with an emphasis on cellular and subcellular targeting. Advances on this front have included the intricate design of targeted NP-drug constructs to navigate through biological barriers, overcome multidrug resistance (MDR), decrease side effects, and improve overall drug efficacy. In this review, we survey advancements in NP-mediated drug targeting over the last five years, highlighting how various NP-drug constructs have been designed to achieve active targeted delivery and improved therapeutic outcomes for critical diseases including cancer, rheumatoid arthritis, and Alzheimer’s disease. We conclude with a survey of the current clinical trial landscape for active targeted NP-drug delivery and how we envision this field will progress in the near future. View Full-Text
Keywords: nanoparticles; active targeted drug delivery; cellular; subcellular; organelles; tumor; cancer; rheumatoid arthritis; Alzheimer’s disease nanoparticles; active targeted drug delivery; cellular; subcellular; organelles; tumor; cancer; rheumatoid arthritis; Alzheimer’s disease
Show Figures

Graphical abstract

MDPI and ACS Style

Nag, O.K.; Delehanty, J.B. Active Cellular and Subcellular Targeting of Nanoparticles for Drug Delivery. Pharmaceutics 2019, 11, 543.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop